SCHEDULE 13D/A: Pfizer Completes Full Divestment of Haleon Stake Through Secondary Offering and Share Buyback

Pfizer Inc. has announced the final divestment of its entire 7.3% beneficial ownership in Haleon plc through a secondary block trade offering of 617.55 million shares and a concurrent share buyback by Haleon of 44 million shares, totaling approximately $220 million.

Summary

• Pfizer Inc. is divesting its remaining 7.3% beneficial ownership in Haleon plc, which amounted to 661,709,764 Ordinary Shares prior to the transaction.
• The divestment will be executed through two primary transactions: a secondary block trade offering and a concurrent share buyback by Haleon.
• In the secondary offering, Pfizer will sell 617,553,920 Ordinary Shares at a price of 385 pence (approximately $5.01) per share.
• Haleon plc will concurrently repurchase approximately 44 million Ordinary Shares from Pfizer for an aggregate purchase price of approximately GBP170 million (approximately $220 million).
• Following the completion of these transactions, Pfizer will cease to beneficially own any Ordinary Shares of Haleon.
• Both the secondary offering and the share buyback are expected to close on March 21, 2025.
• The beneficial ownership percentage was calculated based on 9,054,145,714 Ordinary Shares outstanding as of January 31, 2025.

Sentiment

Score: 7

Explanation: The sentiment is generally positive as it represents the successful execution of a strategic divestment for Pfizer and the removal of a significant shareholder overhang for Haleon, which could be viewed favorably by the market. The transaction is proceeding as expected.

Positives

• For Haleon: The removal of a significant shareholder overhang (Pfizer's 7.3% stake) could improve market liquidity and potentially attract a broader base of institutional investors.
• For Pfizer: The divestment allows Pfizer to fully exit its non-core consumer healthcare business, enabling a sharper focus and allocation of capital towards its core pharmaceutical pipeline and strategic priorities.
• The concurrent share buyback by Haleon demonstrates the company's confidence and ability to return capital, indirectly reducing the number of outstanding shares and potentially enhancing shareholder value.

Negatives

• The large block sale of 617.55 million shares could create short-term selling pressure on Haleon's stock price in the market.
• The transaction involves a significant portion of Haleon's outstanding shares changing hands, which might lead to temporary price volatility.

Risks

• **Market Conditions**: The Managers' obligation to proceed with the offering is subject to various market conditions, including no material adverse change in Haleon's financial condition, earnings, assets, business, operations, or prospects.
• **Trading Suspensions**: The transaction could be terminated if there is any suspension or limitation of trading in Haleon's securities by the London Stock Exchange or the New York Stock Exchange, or generally on these exchanges.
• **Geopolitical and Economic Instability**: Outbreak or material escalation of hostilities, acts of terrorism, declarations of national emergency or war, or other calamities/crises could lead to the termination of the agreement.
• **Financial Market Disruptions**: Material disruptions in commercial banking or securities settlement/clearance services, or adverse changes in financial markets, political/economic conditions, currency exchange rates, or exchange controls, could impede the transaction.
• **Regulatory and Legal Compliance**: The offering relies on exemptions from U.S. Securities Act registration (Regulation S and Rule 144A), requiring strict adherence to these rules, and any non-compliance could pose a risk.

Future Outlook

Following the completion of the March 2025 Secondary Offering and the concurrent March 2025 Share Buyback, Pfizer Inc. will no longer hold any beneficial ownership in Haleon plc, marking a full divestment of its stake.

Industry Context

This divestment represents the final step in Pfizer's strategic exit from the consumer healthcare sector, allowing the pharmaceutical giant to sharpen its focus on its core prescription drug and vaccine businesses. For Haleon, the transaction removes a significant shareholder overhang, potentially increasing its free float and attracting a broader base of institutional investors, solidifying its position as an independent consumer health company.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess the transaction against broader industry standards. The transaction is a specific divestment by a major shareholder rather than a general market performance report.

Related Party Transactions

• Haleon plc's agreement to repurchase approximately 44 million Ordinary Shares from Pfizer Inc. for approximately GBP170 million (approximately $220 million) constitutes a related party transaction, given Pfizer's significant beneficial ownership prior to the divestment.

Stakeholder Impact

• **Shareholders (Haleon)**: The removal of Pfizer as a major shareholder could reduce potential selling pressure and increase the free float, potentially enhancing liquidity and attracting new investors.
• **Shareholders (Pfizer)**: The divestment allows Pfizer to realize value from its Haleon stake and focus capital on its core pharmaceutical business.
• **Investment Banks (Managers)**: The Lead Managers and other Managers will receive a base commission of 0.5% and potentially a discretionary commission of up to 0.25% of the aggregate value of shares sold in the secondary offering.

Next Steps

• Closing of the March 2025 Secondary Offering, expected on March 21, 2025.
• Closing of the March 2025 Share Buyback, expected on March 21, 2025, or as soon as reasonably practicable thereafter.
• Haleon plc is expected to release its Q1 2025 Results on April 30, 2025.

Key Dates

Keywords

Haleon plc, Pfizer Inc., Secondary Offering, Share Buyback, Divestment, Consumer Healthcare, Pharmaceutical, Block Trade, SEC Filing, Schedule 13D, Beneficial Ownership, Equity Sale, Market Liquidity